Marianne Mertens

Marianne Mertens is a seasoned professional in the life sciences industry with extensive experience in venture investing, strategy consulting, and research. Here's an overview of her background and current roles:

Professional Experience

Current Positions:

• Partner at Apollo Health Ventures (joined in 2021)12
• Board Director at HAYA Therapeutics34
• Board Director at Cleara Biotech B.V.1
• Board representative for Apollo Health Ventures on the boards of Haya Therapeutics, Auron, Booster, and Cleara Therapeutics2

Previous Roles:

• Principal at Wellington Partners Life Sciences (2018-2021)1
• Investment Manager at High-Tech Gründerfonds (HTGF)2
• Management consultant supporting pharmaceutical and medical technology companies2

Education

• Bachelor's and Master's degrees in Biotechnology (with distinction) from RWTH Aachen University and The Scripps Research Institute23
• Ph.D. in Biotechnology from RWTH Aachen University (2010-2013), focusing on Experimental Molecular Imaging1
• Executive education in Value Creation in Private Equity and Venture Capital from WHU - Otto Beisheim School of Management (2016)1

Expertise and Contributions

Marianne Mertens has over ten years of experience in the life science industry. Her expertise spans:

• Venture investing in early- and growth-stage life science companies
• Strategy consulting for pharmaceutical and medical technology firms
• Research, particularly in molecular imaging of cardiac regenerative medicines3

In her current role at Apollo Health Ventures, Marianne focuses on accelerating breakthrough scientific discoveries to build life science companies around new therapeutic technologies.1

Achievements

• Led investments into several life sciences companies, including Confo Therapeutics, Imcheck Therapeutics, and Cardior Therapeutics2
• Her Ph.D. research on molecular imaging of cardiac regenerative medicines has been honored with several awards23

Marianne Mertens brings a wealth of experience and expertise to her role as Board Director at HAYA Therapeutics, contributing to the company's mission of developing cutting-edge precision therapeutics.